Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

AHA 2018 ▼Diabetes & CVD ▼Epigenetics in CVD ▼ESC 2018 ▼Expert Meeting GLP-1, CVD & T2DM ▼Invest in your arteries ▼PCSK9 ▼

HoFH

Feb. 8, 2015

Share this page with your colleagues and friends:

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018

Sudden death is the most common cause of death after 30 days post-NSTE-ACS

Literature - Nov. 28, 2018 - Berg DD et al. - Eur Heart J 2018

Atherosclerosis

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

News - Nov. 11, 2018

Virtual histology does not reveal PCSK9 inhibition-induced changes in plaque composition

Literature - Oct. 18, 2018 - Nicholls SJ et al. - J Am Coll Cardiol. 2018

Summary | Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

Munich, Berlin - August 25, 2018

Atrial fibrillation

DOAC treatment safe and effective in AF despite multi-morbidity

Literature - Dec. 4, 2018 - Alexander KP et al. - American Heart Journal 2018

Atrial fibrillation associated with worse long-term CV outcomes in HFmRF and HFpEF

Literature - Oct. 30, 2018 - Zafrir B et al. - Eur Heart J 2018

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

CV Inflammation

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Epicardial fat in HFmrEF and HFpEF patients

News - Dec. 3, 2018

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

CVRM

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

U-Prevent helps predict individual effect of medication on CVD

News - Oct. 16, 2018

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Diabetes

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

ACC Expert Consensus Decision Pathway gives recommendations on use of novel anti-diabetes drugs

News - Dec. 4, 2018

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Updated AHA/ACC cholesterol guidelines focus on more personalized risk assessment

News - Nov. 11, 2018

Final phase 3 study of bempedoic acid met safety and tolerability endpoints

News - Oct. 29, 2018

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

GLP-1 RA & CVD

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark

Twincretin: Superior glycemic control and weight loss compared to GLP-1RA monotherapy in T2DM

Literature - Nov. 26, 2018 - Frias JP et al. - The Lancet 2018

Heart Failure

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018

Epicardial fat in HFmrEF and HFpEF patients

News - Dec. 3, 2018

Sudden death is the most common cause of death after 30 days post-NSTE-ACS

Literature - Nov. 28, 2018 - Berg DD et al. - Eur Heart J 2018

HFpEF: The essentials to know

Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Slides: HFpEF: What is it & size of the problem

Slides (presentation) - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Hypertension

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Age-associated BP rise may be a consequence of Western lifestyle rather than a natural process

Literature - Dec. 3, 2018 - Mueller NT et al. - JAMA Cardiol. 2018

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Lipids

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

Lp(a)

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018

DOAC treatment safe and effective in AF despite multi-morbidity

Literature - Dec. 4, 2018 - Alexander KP et al. - American Heart Journal 2018

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

© 2006 - 2018 pace-cme.org - About